Company ReNeuron Group Plc London S.E.
Equities
Biotechnology & Medical Research
Business Summary
Sales per Business
GBP in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Cell-based Therapies
100.0
%
| 0 | 100.0 % | 1 | 100.0 % | +31.51% |
Sales per region
GBP in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United Kingdom, United States, China and South East Asia
74.3
%
| 0 | 70.5 % | 0 | 74.3 % | +38.73% |
United States
25.7
%
| 0 | 29.5 % | 0 | 25.7 % | +14.29% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
John Hawkins
DFI | Director of Finance/CFO | 58 | 30/09/14 |
Suzanne Hancock
COO | Chief Operating Officer | - | 31/12/16 |
Chief Tech/Sci/R&D Officer | - | 02/03/22 | |
Simon Dew
PRN | Corporate Officer/Principal | - | 31/10/22 |
Shaun Stapleton
LAW | General Counsel | - | 31/07/15 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Martin Walton
BRD | Director/Board Member | 61 | 21/03/22 |
Iain Ross
CHM | Chairman | 71 | 30/06/21 |
Director/Board Member | 61 | 13/07/21 | |
Michael Owen
BRD | Director/Board Member | 73 | 03/12/15 |
John Hawkins
DFI | Director of Finance/CFO | 58 | 30/09/14 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 57,173,760 | 44,745,727 ( 78.26 %) | 0 | 78.26 % |
Company contact information
Sector
Sales per region
1st Jan change | Capi. | |
---|---|---|
+19.47% | 42.68B | |
-3.09% | 42.4B | |
+45.32% | 40.04B | |
-6.20% | 28.31B | |
+7.19% | 24.94B | |
-20.28% | 18.96B | |
+30.21% | 12.3B | |
-2.62% | 11.95B | |
-2.81% | 11.55B |